The company has significantly boosted its course of a novel therapy for amyloid heart disease, employing the investigational drug. Initial clinical information suggests promising outcomes for those suffering from this https://biotech433285.mdkblog.com/48300079/bridgebio-progresses-cardiac-amyloidosis-therapy-through-attruby